Literature DB >> 11168386

Phosphatidylinositol 3-kinases in tumor progression.

D Roymans1, H Slegers.   

Abstract

Many cellular processes have been identified in which phosphatidylinositol 3-kinase has a key regulatory function. As an oncogene, it is also involved in the development of cancer. The transformation and progression of normal cells towards an advanced stage tumor and/or towards metastatic lesions involves a complex series of events, including genetic alterations, leading to aberrant cell cycle progression, altered adhesion and motility characteristics, inhibition of apoptosis and induction of angiogenesis. This review highlights the processes involved in the pathogenesis of cancer in which phosphatidylinositol 3-kinase is involved and provides an overview of the possible mechanisms by which the enzyme exerts its oncogenic action.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11168386     DOI: 10.1046/j.1432-1327.2001.01936.x

Source DB:  PubMed          Journal:  Eur J Biochem        ISSN: 0014-2956


  43 in total

1.  Inducible shRNA expression for application in a prostate cancer mouse model.

Authors:  Frank Czauderna; Ansgar Santel; Michael Hinz; Melanie Fechtner; Birgit Durieux; Gerald Fisch; Frauke Leenders; Wolfgang Arnold; Klaus Giese; Anke Klippel; Jörg Kaufmann
Journal:  Nucleic Acids Res       Date:  2003-11-01       Impact factor: 16.971

2.  The C2A domain of JFC1 binds to 3'-phosphorylated phosphoinositides and directs plasma membrane association in living cells.

Authors:  Sergio D Catz; Jennifer L Johnson; Bernard M Babior
Journal:  Proc Natl Acad Sci U S A       Date:  2002-08-20       Impact factor: 11.205

3.  Functional studies of the PI(3)-kinase signalling pathway employing synthetic and expressed siRNA.

Authors:  Frank Czauderna; Melanie Fechtner; Hüseyin Aygün; Wolfgang Arnold; Anke Klippel; Klaus Giese; Jörg Kaufmann
Journal:  Nucleic Acids Res       Date:  2003-01-15       Impact factor: 16.971

4.  A new crucial protein interaction element that targets the adenovirus E4-ORF1 oncoprotein to membrane vesicles.

Authors:  Sang-Hyuk Chung; Kristopher K Frese; Robert S Weiss; B V Venkataram Prasad; Ronald T Javier
Journal:  J Virol       Date:  2007-02-21       Impact factor: 5.103

5.  N-benzoxazol-2-yl-N'-1-(isoquinolin-3-yl-ethylidene)-hydrazine, a novel compound with antitumor activity, induces radicals and dissipation of mitochondrial membrane potential.

Authors:  Johann Hofmann; Johnny Easmon; Gerhard Puerstinger; Gottfried Heinisch; Marcel Jenny; Alexander A Shtil; Martin Hermann; Daniele F Condorelli; Salvatore Sciré; Giuseppe Musumarra
Journal:  Invest New Drugs       Date:  2008-07-09       Impact factor: 3.850

Review 6.  Targeting mTOR network in colorectal cancer therapy.

Authors:  Xiao-Wen Wang; Yan-Jie Zhang
Journal:  World J Gastroenterol       Date:  2014-04-21       Impact factor: 5.742

7.  Akt-PDK1 complex mediates epidermal growth factor-induced membrane protrusion through Ral activation.

Authors:  Hisayoshi Yoshizaki; Naoki Mochizuki; Yukiko Gotoh; Michiyuki Matsuda
Journal:  Mol Biol Cell       Date:  2006-11-01       Impact factor: 4.138

8.  Effects of PI3-k/Akt short hairpin RNA on proliferation, fibronectin production and synthesis of thrombospondin-1 and transforming growth factor-beta1 in glomerular mesangial cells induced by sublytic C5b-9 complexes.

Authors:  L Gao; Y Zhang; W Qiu; W Xu; X Feng; J Ren; X Jiang; H Wang; D Zhao; Y Wang
Journal:  Cell Prolif       Date:  2009-02       Impact factor: 6.831

9.  Mechanisms of nuclear vitamin D receptor resistance in Harvey-ras-transfected cells.

Authors:  Laura M Taber; Lynn S Adams; Dorothy Teegarden
Journal:  J Nutr Biochem       Date:  2008-10-01       Impact factor: 6.048

10.  Quercetin may suppress rat aberrant crypt foci formation by suppressing inflammatory mediators that influence proliferation and apoptosis.

Authors:  Cynthia A Warren; Kimberly J Paulhill; Laurie A Davidson; Joanne R Lupton; Stella S Taddeo; Mee Young Hong; Raymond J Carroll; Robert S Chapkin; Nancy D Turner
Journal:  J Nutr       Date:  2008-12-03       Impact factor: 4.798

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.